Stoke Therapeutics (STOK) Cash & Equivalents (2018 - 2026)

Stoke Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $155.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 43.36% year-over-year to $155.7 million; the trailing twelve-month figure through Mar 2026 stood at $155.7 million (down 43.36% YoY), and the FY2025 full-year result was $84.2 million, down 34.19% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $155.7 million, up from $84.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $274.8 million in Q1 2025, with the low at $67.8 million in Q2 2022.
• Average Cash & Equivalents over 5 years is $146.6 million, with a median of $150.0 million recorded in 2024.
• Year-over-year, Cash & Equivalents slumped 68.56% in 2022 and soared 183.47% in 2023.
• Tracing STOK's Cash & Equivalents over 5 years: stood at $113.6 million in 2022, then jumped by 68.59% to $191.4 million in 2023, then tumbled by 33.15% to $128.0 million in 2024, then plunged by 34.19% to $84.2 million in 2025, then soared by 84.82% to $155.7 million in 2026.
• The last three Cash & Equivalents figures came in at $155.7 million (Q1 2026), $84.2 million (Q4 2025), and $83.4 million (Q3 2025), per Business Quant data.

Peer Comparison